MedTrace Logo

Casein Glycomacropeptide in Healthy Subjects

NCT02832700 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2019-06-10

No results posted yet for this study

Summary

Casein glycomacropeptide (CGMP) has anti-inflammatory properties in experimental rodent colitis and using human in vitro inflammation models. Its use as a food ingredient has proven safe and with no influence on dietary intake. In a pilot study the investigators found, that orally administered CGMP seems to have a beneficial effect comparable to that of mesalazine in active distal ulcerative colitis.

The investigators now wish to evaluate the effects in healthy subjects by studying the anti-inflammatory and microbiome modulating properties and by assessing possible changes in gastrointestinal symptoms.

Conditions

  • Gastrointestinal Disease

Interventions

DIETARY_SUPPLEMENT

Casein glycomacropeptide

DIETARY_SUPPLEMENT

Placebo

Sponsors & Collaborators

  • Arla Foods

    collaborator INDUSTRY

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Hendrik A Vilstrup, Professor · University of Aarhus

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2017-09-01
Completion
2017-09-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02832700 on ClinicalTrials.gov